Evidence map›Paper›PMID 36799165›Full record

ArticleInternational journal of oncology2023

Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer.

Neshat Masud, Afaf Aldahish, Kenneth A Iczkowski, Ajay Kale, Girish V Shah

RetractedOpen access · hybridAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Neshat MasudPharmacology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209, USA.
Afaf AldahishPharmacology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209, USA.
Kenneth A IczkowskiPathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Ajay KalePharmacology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209, USA.
Girish V ShahPharmacology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209, USA.
University of Louisiana at Monroe · USMedical College of Wisconsin · US

Funding

Calcitonin in Prostate Growth and NeplasiaR01CA096534 · NCI · UNIVERSITY OF LOUISIANA AT MONROE · PI SHAH, GIRISH V · 2001 to 2013
$1.4M
Calcitonin in Prostate Growth and NeoplasiaR56CA096534 · NCI · UNIVERSITY OF LOUISIANA AT MONROE · PI SHAH, GIRISH V · 2008 to 2008
$175k
NCI NIH HHS R01 CA096534NCI NIH HHS R56 CA096534
6 · The paper itself

Abstract

Prostate‑derived calcitonin (CT) and its receptor induce tumorigenicity and increase metastatic potential of prostate cancer (PC). CT‑inducible genes in human prostate were identified by subtraction hybridization. Among these genes, zinc finger protein like 1 (ZFPL1) protein was interesting since it was abundantly expressed in malignant prostates but was almost absent in benign prostates. ZFPL1 expression was upregulated by CT and androgens, and ZFPL1 protein was secreted by prostate tumor cells through exosomal secretion. Serum levels of ZFPL1 in cancer patients were at least 4‑fold higher than those in the sera of cancer‑free individuals. Cell biology of ZFPL1 suggests its localization in Golgi bodies and exosomes, and its colocalization with chromogranin A and CD44. These results suggested that ZFPL1 is secreted by tumor cells of neuroendocrine (NE)/stem cell phenotype. The knockdown of endogenous ZFPL1 in (PC) cells led to a remarkable decrease in cell proliferation, and invasion while increasing their apoptosis. As expected, the overexpression of ZFPL1 in prostate cells had an opposite effect on these functions. The knockdown of ZFPL1 in PC cells also decreased Akt phosphorylation, suggesting the actions of ZFPL1 may be mediated through the PI3K‑Akt pathway. Moreover, the present results revealed that ZFPL1 is released by tumors cells of NE or androgen‑independent phenotype and its serum levels are significantly higher in cancer patients, suggesting that it may serve as a blood‑based non‑invasive biomarker of aggressive PC.

Indexed as

DNA-Binding ProteinsProstatic NeoplasmsProto-Oncogene Proteins c-aktAndrogensBiomarkersHumansMalePhosphatidylinositol 3-KinasesZinc FingersAndrogensBiomarkersDNA-Binding ProteinsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktZFPL1 protein, humancalcitonincancer markerneuroendocrineprostate cancerzinc finger protein like 1

Identifiers

PMID36799165
PMCPMC9937688
OpenAlexW4319296532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.